Envafolimab Combined With GEMOX in First-line Treatment of Advanced GBC

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 17, 2023

Primary Completion Date

May 31, 2025

Study Completion Date

December 31, 2025

Conditions
Gallbladder Cancer
Interventions
DRUG

Envafolimab+Gemox

"All of drugs were used for 6-8 cycles at the combined treatment stage, then Envafolimab and Gemcitabine continued at maintenance treatment stage until disease progression as defined by RECIST1.1, unacceptable toxicity, withdrawal from the study or death, or no more than 1 years.~Combined treatment stage: Envafolimab(150mg, iH, Q1W, Day1)+Gemcitabine(1000mg/m2, iv, Q3W, Day1 and Day8)+Cisplatin(1000mg/m2, iv, Q3W, Day1 and Day8);~Caintenance treatment stage: Envafolimab(400mg, iH, Day1, Q3W)+Gemcitabine(1000mg/m2, po, Day1-14, Q3W)."

Trial Locations (1)

200438

RECRUITING

Easter hepatobiliary surgery hospital, Shanghai

All Listed Sponsors
lead

Eastern Hepatobiliary Surgery Hospital

OTHER